Medications
Subcutaneous nivolumab as effective as IV for renal cell carcinoma, with much faster treatment time: Clinical trial
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large ...
Jan 29, 2024
0
0